Every drug, company and target in the pharma pipeline, and who needs a new molecule.
Edition of 20 October 2026 · rebuilt monthly from public registers · Method
This edition
20 October 2026Browse the database
Drugs · companies · targets · areas · yearsMarketed drugs, by the year their US protection ends
The year of the latest counted date, not the date generics or biosimilars can enter. Marked computed where it is worked out from the first US licence.
Companies with no follow-on: companies that market a drug at this target and have no successful follow-on of their own there (route B). Which companies they are is part of a plan.
All years, 2026 to 2035Companies
Where each company has a drug that failed or went quiet (route A), or a marketed drug with no follow-on (route B).
Targets
The protein a drug acts on, with the number of companies that need a new molecule for it, by route.
Drugs
Every drug in the pipeline, past and present, with where it stands.
Therapeutic areas
Targets grouped by the part of the body or the kind of disease they relate to.
Pages for each area open soon. Request access to see them now.
What you get when you sign in
Everything above stays open to readWhich companies, ranked with the evidence behind each
All 4,815 company–target needs, each with the facts, sources and dates it rests on, and what is still open.
Exact dates and the listings behind them
For each of the 59 drugs losing US protection in 2027, and for every other year, the exact date and the register entries it comes from.
Agents that work through a list for you
Give an agent a task over the database and it returns a report in which every claim cites its fact. Institutional plan, in early access.